LMR Partners LLP Acquires Shares of 43,790 UiPath Inc. (NYSE:PATH)

LMR Partners LLP bought a new position in UiPath Inc. (NYSE:PATH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 43,790 shares of the healthcare company’s stock, valued at approximately $561,000.

A number of other large investors have also recently made changes to their positions in the company. Quest Partners LLC raised its holdings in shares of UiPath by 181.4% in the third quarter. Quest Partners LLC now owns 27,756 shares of the healthcare company’s stock worth $355,000 after buying an additional 17,893 shares during the period. Thrivent Financial for Lutherans increased its stake in UiPath by 10.6% in the third quarter. Thrivent Financial for Lutherans now owns 20,881 shares of the healthcare company’s stock worth $267,000 after purchasing an additional 1,995 shares during the period. Oppenheimer & Co. Inc. lifted its position in shares of UiPath by 5.2% during the third quarter. Oppenheimer & Co. Inc. now owns 195,641 shares of the healthcare company’s stock worth $2,504,000 after purchasing an additional 9,709 shares during the last quarter. Nations Financial Group Inc. IA ADV boosted its stake in shares of UiPath by 6.8% during the third quarter. Nations Financial Group Inc. IA ADV now owns 26,090 shares of the healthcare company’s stock valued at $334,000 after purchasing an additional 1,654 shares during the period. Finally, Versor Investments LP bought a new position in shares of UiPath in the third quarter worth about $266,000. 62.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PATH shares. Evercore ISI lifted their price objective on shares of UiPath from $13.00 to $16.00 and gave the company an “in-line” rating in a report on Friday, September 6th. BMO Capital Markets boosted their price target on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a report on Friday, September 6th. Barclays raised their price objective on UiPath from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Friday, September 6th. Wells Fargo & Company lowered their target price on UiPath from $15.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Finally, DA Davidson raised their price target on UiPath from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $17.47.

UiPath Stock Performance

Shares of PATH stock opened at $12.76 on Wednesday. UiPath Inc. has a fifty-two week low of $10.37 and a fifty-two week high of $27.87. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of -63.77 and a beta of 0.87. The stock’s 50-day simple moving average is $12.63 and its 200-day simple moving average is $13.25.

UiPath (NYSE:PATH) last released its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The company had revenue of $316.00 million for the quarter, compared to the consensus estimate of $303.69 million. During the same quarter in the previous year, the firm earned ($0.09) EPS. UiPath’s revenue was up 10.0% compared to the same quarter last year. As a group, equities analysts forecast that UiPath Inc. will post -0.23 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Ashim Gupta sold 47,671 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the transaction, the chief financial officer now owns 849,917 shares in the company, valued at approximately $10,258,498.19. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 22.37% of the stock is currently owned by insiders.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.